An open-label, phase I/IIa study of BI-1206 in combination with rituximab in patients with relapsed or refractory Non-Hodgkin Lymphoma (NHL)

Trial Profile

An open-label, phase I/IIa study of BI-1206 in combination with rituximab in patients with relapsed or refractory Non-Hodgkin Lymphoma (NHL)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs BI 1206 (Primary) ; Rituximab
  • Indications Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioInvent International
  • Most Recent Events

    • 01 Nov 2017 New trial record
    • 23 Oct 2017 According to a BioInvent International media release, this trial is planned to start in H1 2018, and the last patient is expected to finish the trial before the end of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top